Xeris Biopharma Holdings, Inc. (XERS) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
XERS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
XERS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 81.7% | 8.5% | 0.2% |
| 2024 | 81.9% | -16.6% | -27.0% |
| 2023 | 82.5% | -26.8% | -38.0% |
| 2022 | 79.5% | -74.3% | -85.9% |
| 2021 | 73.1% | -232.2% | -247.5% |
Download Data
Export XERS earnings history in CSV or JSON format
Free sign-in required to download data
Xeris Biopharma Holdings, Inc. (XERS) Earnings Overview
As of May 8, 2026, Xeris Biopharma Holdings, Inc. (XERS) reported trailing twelve-month net income of $12M, reflecting +100.9% year-over-year growth. The company earned $0.07 per diluted share over the past four quarters, with a net profit margin of 0.2%.
Looking at the long-term picture, XERS's historical earnings data spans multiple years. The company achieved its highest annual net income of $554,000 in fiscal 2025, representing a new all-time high.
Xeris Biopharma Holdings, Inc. maintains positive profitability with a gross margin of 81.7%, operating margin of 8.5%, and net margin of 0.2%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including LNTH ($279M net income, 15.2% margin), SUPN (-$29M net income, -5.4% margin), PAHC ($92M net income, 3.7% margin), XERS has room to improve margins relative to the peer group. Compare XERS vs LNTH →
XERS Earnings vs Peers
Earnings metrics vs comparable public companies
XERS Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $554,000 | +101.0% | $25M | $0.00 | 0.2% | 8.5% |
| 2024 | -$55M | +11.9% | -$34M | $-0.37 | -27.0% | -16.6% |
| 2023 | -$62M | +34.2% | -$44M | $-0.45 | -38.0% | -26.8% |
| 2022 | -$95M | +22.9% | -$82M | $-0.70 | -85.9% | -74.3% |
| 2021 | -$123M | -34.7% | -$115M | $-1.55 | -247.5% | -232.2% |
| 2020 | -$91M | +27.4% | -$84M | $-2.14 | -446.0% | -408.8% |
| 2019 | -$126M | -109.0% | -$122M | $-3.49 | -4613.5% | -4496.0% |
| 2018 | -$60M | -126.3% | -$59M | $-4.99 | -2437.3% | -2407.5% |
| 2017 | -$27M | -101.0% | -$27M | $-13.09 | -1706.6% | -1711.4% |
| 2016 | -$13M | - | -$13M | $-7.17 | -1228.7% | -1230.8% |
See XERS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XERS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XERS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXERS — Frequently Asked Questions
Quick answers to the most common questions about buying XERS stock.
Is XERS growing earnings?
XERS EPS is $0.07, with earnings growth accelerating to +100.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $12M.
What are XERS's profit margins?
Xeris Biopharma Holdings, Inc. net margin is +0.2%, with operating margin at +8.5%. Below-average margins reflect competitive or cost pressures.
How consistent are XERS's earnings?
XERS earnings data spans 2016-2025. The accelerating earnings trend is +100.9% YoY. Historical data enables comparison across business cycles.